Experimental group:Bufei Huoxue Capsule, 1.4g/day, three times a day, three months of treatment

2 trials

Sponsors

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Early Phase 1

A randomized, double-blind, controlled trial for Bufei Huoxue Capsule in the treatment of convalescent COVID-19 patients

RecruitingChiCTR2000032573

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, ChinaNovel Coronavirus Pneumonia (COVID-19)

Start: 2020-05-02Updated: 2021-01-25

A randomized, double-blind, controlled trial for Bufei Huoxue Capsule in the treatment of convalescent COVID-19 patients

RecruitingITMCTR2100004294

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, ChinaNovel Coronavirus Pneumonia (COVID-19)

Start: 2020-05-02Updated: 2023-02-20

Related Papers

A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19”

Pulmonary Circulation2025-04-01

Bufei huoxue capsules in the management of convalescent COVID‐19 infection: study protocol for a multicenter, double‐blind, and randomized controlled trial

Pulmonary Circulation2021-07-017 citations